Clinical Chemistry and Laboratory Medicine (CCLM)
Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Editor-in-Chief: Plebani, Mario
Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.
12 Issues per year
IMPACT FACTOR 2016: 3.432
CiteScore 2016: 2.21
SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112
Current state and future directions of neurochemical biomarkers for Alzheimer's disease
- 4Department of Neurology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands, Alzheimer Center Nijmegen, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands and Laboratory of Pediatrics and Neurology, Radboud University Nijmegen Medical Center, The Netherlands
- Other articles by this author:
- De Gruyter OnlineGoogle Scholar
In this comprehensive review, we summarize the current state-of-the-art of neurochemical biomarkers for Alzheimer's disease. Predominantly, these biomarkers comprise cerebrospinal fluid biomarkers directly related to the pathophysiology of this disorder (such as amyloid β protein, tau protein). We particularly pay attention to the innovations in this area that have been made in technological aspects during the past 5 years (e.g., multiplex analysis of biomarkers, proteomics), to the discovery of novel, potential biomarkers (e.g., amyloid β oligomers, isoprostanes), and to the extension of this research towards identification of biomarkers in plasma.
Clin Chem Lab Med 2007;45:1421–34.
Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.